Brixton Biosciences
PrivateLast Round
Grant
Oct 24, 2024
Total Funding Raised
$35M
Momentum Score
25 /100
Company Overview
Brixton Biosciences is a biotechnology company focused on developing innovative therapies for chronic and acute pain relief through a simple injection that offers extended pain management lasting from thirty to sixty days.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share, Hardware Sales, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Brixton Biosciences Comps
Public and private peers based on sector, stage, and business model.
Brixton Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 24, 2024 | ||||
| Series B | May 14, 2024 |
Key People
Founding team and executive leadership
Brixton Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B |
| NIH RADx | Grant |
| Pritzker Vlock Family Office | Series B |
| Schooner Capital | Series B |
| Catalyst Health Ventures | Series B |
| Excelestar Ventures | Series B |
Brixton Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Brixton Biosciences's valuation, stock price, and market status.
